Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy
- 8 October 2015
- journal article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Gastroenterology
- Vol. 51 (3), 329-336
- https://doi.org/10.3109/00365521.2015.1095351
Abstract
Autoimmune hepatitis (AIH) is an immune-mediated liver disease, which requires long-term immunosuppression. Ten to fifteen percent of patients experience insufficient/intolerance response to standard therapy. Although alternate immunosuppression has been applied, there is little long-term data reported on safety, efficacy, steroid-dose reduction and disease evolution in patients with difficult AIH who were on Tacrolimus therapy. Clinical, biochemical, immunological profiles, treatment response and side effects of 17 AIH patients treated with Tacrolimus between 2003 and 2014 were analyzed from two tertiary referral liver centers. Tacrolimus was started on 16/17 (94%) patients due to insufficient response to standard therapy. The median duration of treatment was 24 months and patients were followed up for median of 60 months. Tacrolimus dosage was 2 mg/day (median). During first year of therapy, there was a significant improvement in immunoglobulin G and Aspartate transaminase level. 9/17 (52%) compliant and definite AIH patients remained on Tacrolimus at end of follow-up and prednisolone dose reduction was achieved from 10 to 5 mg. All patients are alive and one patient underwent liver transplantation. 4/17 (24%) patients developed overlap with primary sclerosing cholangitis over follow-up period. No significant side effects were observed with Tacrolimus therapy. Tacrolimus could be used in compliant patients with difficult to treat AIH in experienced centers. Its use is safe and can improve liver biochemistry, IgG and reduce steroid requirement. However, due to the lack of immunomodulatory effect, unmet need for effective immune-regulatory therapies still remain for AIH patients.Keywords
This publication has 28 references indexed in Scilit:
- Autoimmune hepatitis – Update 2015Journal of Hepatology, 2015
- Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and ManagementGastroenterology, 2013
- Regulatory T cells and autoimmune hepatitis: Defective cells or a hostile environment?Journal of Hepatology, 2012
- Pharmacological management of autoimmune hepatitisExpert Opinion on Pharmacotherapy, 2011
- Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and managementHepatology International, 2010
- Distinct Roles for CCR4 and CXCR3 in the Recruitment and Positioning of Regulatory T Cells in the Inflamed Human LiverJournal Of Immunology, 2010
- Diagnosis and management of autoimmune hepatitisHepatology, 2010
- Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment responseScandinavian Journal of Gastroenterology, 2010
- Regulatory T Cells and Immune ToleranceCell, 2008
- Diagnosis and treatment of autoimmune hepatitisHepatology, 2002